The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials
Open accessAbstract
BACKGROUND: Early‐phase trials in patients with recurrent neuroblastoma historically used an objective “response” of measureable disease (Response Evaluation Criteria In Solid Tumors [RECIST], without bone/bone marrow assessment) to select agents for further study. Historical cohorts may be small and potentially biased; to the authors' knowledge, disease recurrence studies from international registries are outdated. Using a large recent cohort of patients with recurrent/refractory neuroblastoma from Children's Oncology Group (COG) modern‐era early‐phase trials, the authors determined outcome and quantified parameters for designing future studies. METHODS: The first early‐phase COG trial enrollment (sequential) of 383 distinct patients with recurrent/refractory neuroblastoma on 23 phase 1, 3 phase 1/2, and 9 phase 2 trials (August 2002 to January 2014) was analyzed for progression‐free survival (PFS), overall survival (OS), and time to disease progression (TTP). Planned frontline therapy for patients with high‐risk neuroblastoma included hematopoietic stem cell transplantation (approximately two‐thirds of patients underwent ≥1 hematopoietic stem cell transplantation); 13.2% of patients received dinutuximab. RESULTS: From the time of the patient's first early‐phase trial enrollment (383 patients), the 1‐year and 4‐year PFS rates ( ± standard error) were 21% ± 2% and 6% ± 1%, respectively, whereas the 1‐year and 4‐year OS rates were 57% ± 3% and 20% ± 2%, respectively. The median TTP was 58 days (interquartile range, 31‐183 days [350 patients]); the median follow‐up was 25.3 months (33 patients were found to be without disease recurrence/progression). The median time from diagnosis to first disease recurrence/progression was 18.7 months (range, 1.4‐64.8 months) (176 patients). MYCN amplification and 11q loss of heterozygosity were prognostic of worse PFS and OS (P = .003 and P<.0001, respectively, and P = .02 and P = .03, respectively) after early‐phase trial enrollment. CONCLUSIONS: This recent COG cohort of patients with recurrent/refractory neuroblastoma is inclusive and representative. To the authors' knowledge, the current study is the first meta‐analysis of PFS, TTP, and OS within the context of modern therapy. These results will inform the design of future phase 2 studies by providing a) historical context during the search for more effective agents; and, b) factors prognostic of PFS and OS after disease recurrence to stratify randomization. Cancer 2017;123:4914‐23. © 2017 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Self-citationLondon, W. B., Castel, V., Monclair, T., Ambros, P. F., Pearson, A. D. J., Cohn, S. L., Berthold, F., Nakagawara, A., Ladenstein, R. L., Iehara, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3392 · Cited by 318
Self-citation
Cited by
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
Del Bufalo, F., De Angelis, B., Caruana, I., Del Baldo, G., De Ioris, M. A., Serra, A., Mastronuzzi, A., Cefalo, M. G., Pagliara, D., Amicucci, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2210859 · Cited by 561
Advancing therapy for neuroblastoma
Qiu, B., & Matthay, K. K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00643-z · Cited by 407
Park, J. R., Kreissman, S. G., London, W. B., Naranjo, A., Cohn, S. L., Hogarty, M. D., Tenney, S. C., Haas-Kogan, D., Shaw, P. J., Kraveka, J. M., et al. (2019) · JAMA · doi:10.1001/jama.2019.11642 · Cited by 358
Self-citationEk, T., Ibrahim, R. R., Vogt, H., Georgantzi, K., Träger, C., Gaarder, J., Djos, A., Rahmqvist, I., Mellström, E., Pujol-Calderón, F., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0338 · Cited by 15
Metadata
- Authors
- London, W. B., Bagatell, R., Weigel, B. J., Fox, E., Guo, D., Van Ryn, C., Naranjo, A., & Park, J. R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2017-09-08
- Volume
- 123
- Issue
- 24
- Pages
- 4914-4923
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2752617269
- Cited by
- 175
- References
- 3
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.